SpineVision raises $5M

Paris-based SpineVision has raised $5 million and will use the money to accelerate market penetration of its next-generation devices for spinal treatment. The funds come from Partner Capital, Sofinnova, BroadPeak, HealthCap, Innoven, Edbi and other individuals.

"We now have a focused and streamlined international operation that is steadfastly penetrating the market for minimally invasive and motion-preservation spinal therapies," says Gérard Hascoët, chairman and CEO of SpineVision, in a statement. "Flex+ is an ingenious dynamic-stabilization system that offers multiple stabilizing options in concert with our equally innovative minimally invasive screw system, LUMIS."

Flex+ Hybrid uses technology that enables the combination of rigid and flexible parts in one low-profile implant. "As such, Flex+ used in combination with LUMIS is a unique solution allowing to preempt pathologies at adjacent levels by protecting the adjacent discs, and to improve patient outcome by reducing the need for a large incision," explains Arnaud Brisard, COO of SpineVision.

As the company notes on its website, new market opportunities and the quality of its current product lines is allowing SpineVision to focus its R&D efforts on motion preservation and minimally invasive technologies.

- see the SpineVision statement

Suggested Articles

Boehringer Ingelheim tapped Healx to help identify new drug indications and leverage its AI to explore R&D options in neurological diseases.

CMR Surgical will have a new CEO at the top of the year, as it kicks off the global launch of its modular Versius system while awaiting FDA approval.

The ADDF announced its second round of research awards, with a total of $6 million in new funding for diagnostic tests.